What is Zacks Research’s Estimate for IOVA Q1 Earnings?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Research analysts at Zacks Research cut their Q1 2025 earnings estimates for Iovance Biotherapeutics in a research report issued to clients and investors on Wednesday, March 19th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will earn ($0.26) per share for the quarter, down from their previous estimate of ($0.25). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.24) per share. Zacks Research also issued estimates for Iovance Biotherapeutics’ Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.87) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.10) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.37) EPS.

Several other research analysts have also recently issued reports on the company. The Goldman Sachs Group decreased their price target on Iovance Biotherapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Robert W. Baird decreased their target price on shares of Iovance Biotherapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Friday, February 28th. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a research report on Friday, February 28th. Piper Sandler decreased their price objective on shares of Iovance Biotherapeutics from $7.50 to $6.00 and set a “neutral” rating for the company in a report on Friday, February 28th. Finally, Chardan Capital dropped their target price on Iovance Biotherapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $20.25.

Iovance Biotherapeutics Price Performance

Shares of IOVA stock opened at $3.48 on Monday. The business has a 50 day simple moving average of $5.03 and a 200 day simple moving average of $7.66. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of -2.34 and a beta of 0.93. Iovance Biotherapeutics has a 12-month low of $3.42 and a 12-month high of $15.18.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) EPS for the quarter, hitting the consensus estimate of ($0.26). The firm had revenue of $73.69 million during the quarter, compared to analysts’ expectations of $72.17 million. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of IOVA. California State Teachers Retirement System grew its holdings in shares of Iovance Biotherapeutics by 7.3% in the 4th quarter. California State Teachers Retirement System now owns 203,241 shares of the biotechnology company’s stock worth $1,504,000 after acquiring an additional 13,774 shares during the last quarter. Arcadia Wealth Management Inc. purchased a new position in Iovance Biotherapeutics in the 4th quarter worth about $117,000. B. Riley Wealth Advisors Inc. raised its holdings in Iovance Biotherapeutics by 39.4% during the 4th quarter. B. Riley Wealth Advisors Inc. now owns 19,442 shares of the biotechnology company’s stock worth $144,000 after buying an additional 5,500 shares during the period. GF Fund Management CO. LTD. purchased a new stake in Iovance Biotherapeutics during the fourth quarter valued at about $47,000. Finally, Neo Ivy Capital Management purchased a new stake in Iovance Biotherapeutics during the fourth quarter valued at about $3,353,000. Institutional investors own 77.03% of the company’s stock.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.